EBS (Emergent BioSolutions) Cyclically Adjusted FCF per Share: $1.16 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EBS Emergent BioSolutions Inc EBS
61 GF Score
Price $5.31
GF Value $5.62
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Emergent BioSolutions Cyclically Adjusted FCF per Share?

Emergent BioSolutions EBS -29.58% 61 Cyclically Adjusted FCF per Share is $1.16 as of Jun. 2026. GuruFocus rates EBS with a GF Score™ of 61/100 and a GF Value™ of $5.62 (Fairly Valued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Emergent BioSolutions's adjusted free cash flow per share for the three months ended in Jun. 2026 was $1.047. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $1.16 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Emergent BioSolutions's average Cyclically Adjusted FCF Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -11.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -10.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 13.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Emergent BioSolutions was 43.60% per year. The lowest was -24.80% per year. And the median was 13.25% per year.

As of today (2026-08-07), Emergent BioSolutions's current stock price is $5.31. Emergent BioSolutions's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was $1.16. Emergent BioSolutions's Cyclically Adjusted Price-to-FCF of today is 4.58.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Emergent BioSolutions was 134.77. The lowest was 1.81. And the median was 47.67.


Emergent BioSolutions  (NYSE:EBS) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Emergent BioSolutions's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=5.31/1.16
=4.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Emergent BioSolutions was 134.77. The lowest was 1.81. And the median was 47.67.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Emergent BioSolutions Cyclically Adjusted FCF per Share Related Terms


Emergent BioSolutions Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Emergent BioSolutions's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions Cyclically Adjusted FCF per Share Chart

Emergent BioSolutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.67 1.53 0.86 0.71 1.08

Emergent BioSolutions Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.18 0.92 1.08 0.97 1.16

EBS vs EOLS, ELTP, AKBA: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Cyclically Adjusted Price-to-FCF falls into.


EBS
61GF Score
Emergent BioSolutions Inc EBS
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emergent BioSolutions Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Emergent BioSolutions's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.047/333.9520*333.9520
=1.047

Current CPI (Jun. 2026) = 333.9520.

Emergent BioSolutions Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 0.204 241.428 0.282
201612 -0.643 241.432 -0.889
201703 0.430 243.801 0.589
201706 0.893 244.955 1.217
201709 0.439 246.819 0.594
201712 1.278 246.524 1.731
201803 -0.254 249.554 -0.340
201806 0.410 251.989 0.543
201809 2.872 252.439 3.799
201812 -3.588 251.233 -4.769
201903 1.629 254.202 2.140
201906 -0.969 256.143 -1.263
201909 -0.352 256.759 -0.458
201912 1.632 256.974 2.121
202003 0.646 258.115 0.836
202006 1.735 257.797 2.248
202009 1.096 260.280 1.406
202012 3.844 260.474 4.928
202103 -0.936 264.877 -1.180
202106 -1.791 271.696 -2.201
202109 -0.717 274.310 -0.873
202112 5.277 278.802 6.321
202203 -1.371 287.504 -1.592
202206 -0.954 296.311 -1.075
202209 -2.042 296.808 -2.298
202212 1.390 296.797 1.564
202303 -3.966 301.836 -4.388
202306 -2.503 305.109 -2.740
202309 0.915 307.789 0.993
202312 0.397 306.746 0.432
202403 -1.406 312.332 -1.503
202406 0.816 314.175 0.867
202409 2.660 315.301 2.817
202412 -1.506 315.605 -1.594
202503 -0.258 319.799 -0.269
202506 1.910 322.561 1.977
202509 -0.101 324.800 -0.104
202512 1.302 324.054 1.342
202603 -0.641 330.213 -0.648
202606 1.047 333.952 1.047

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $1.16 mean?
Emergent BioSolutions (EBS) has a Cyclically Adjusted FCF per Share of $1.16 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Emergent BioSolutions and its competitors.
Is Emergent BioSolutions' Cyclically Adjusted FCF per Share too high?
Emergent BioSolutions' current Cyclically Adjusted FCF per Share is $1.16. Overall, Emergent BioSolutions has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Cyclically Adjusted FCF per Share compare to EOLS and ELTP?
Emergent BioSolutions' Cyclically Adjusted FCF per Share of $1.16 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Emergent BioSolutions and its competitors. Emergent BioSolutions's current Cyclically Adjusted FCF per Share is $1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (EBS) is currently considered Fairly Valued. The stock's GF Value™ is $5.62, compared to a current price of $5.31 — trading 5.5% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $1.16. Emergent BioSolutions' overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Emergent BioSolutions (EBS), the current Cyclically Adjusted FCF per Share is $1.16 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Emergent BioSolutions (EBS) Overvalued in 2026?

Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be undervalued. The current stock price of $5.31 is trading 5.5% below its estimated GF Value™ of $5.62. GuruFocus considers Emergent BioSolutions to be Fairly Valued.

Key valuation signals for EBS:

  • Cyclically Adjusted FCF per Share: $1.16
  • GF Value™: $5.62 vs. price of $5.31 (5.5% below fair value)
  • GF Score™: 61/100 with 7 warning signs

No single metric tells the full story. See the EBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Emergent BioSolutions Business Description

Other Exchanges 0IGA:UKER4:Germany
Address 300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
61GF Score

Get the complete analysis for EBS

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.31
Price
$5.62
GF Value